FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Julia A BeaverPatricia Cortazar

Abstract

On February 3, 2015, the FDA granted accelerated approval to palbociclib (IBRANCE, Pfizer Inc.), an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. The approval is based on a randomized, multicenter, open-label phase I/II trial (PALOMA-1) in 165 patients randomized to palbociclib (125 mg orally daily for 21 consecutive days, followed by 7 days off treatment) plus letrozole (2.5 mg orally daily) or letrozole alone. The phase II portion of the trial was divided into two cohorts: cohort 1 enrolled 66 biomarker-unselected patients and cohort 2 enrolled 99 biomarker-positive patients. The major efficacy outcome measure was investigator-assessed progression-free survival (PFS). A large magnitude of improvement in PFS was observed in patients receiving palbociclib plus letrozole compared with patients receiving letrozole alone (HR, 0.488; 95% confidence interval, 0.319-0.748). Multiple sensitivity analyses were supportive of clinical benefit. The most common adverse reaction in patients receiving palboci...Continue Reading

References

Jul 1, 1999·Genes & Development·C J Sherr, J M Roberts
Nov 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BonneterreM von Euler
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew Arnold, Alexandros Papanikolaou
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Sep 17, 2014·Breast Cancer Research : BCR·Agnieszka K Witkiewicz, Erik S Knudsen
Jun 2, 2015·The New England Journal of Medicine·Nicholas C TurnerUNKNOWN PALOMA3 Study Group

❮ Previous
Next ❯

Citations

Dec 19, 2015·Expert Opinion on Pharmacotherapy·Guenther G StegerRupert Bartsch
Dec 17, 2015·Clinical and Translational Medicine·Saveri BhattacharyaTimothy F Burns
Mar 19, 2016·Future Oncology·Ioannis ZerdesDimitrios H Roukos
May 14, 2016·Journal of Medicinal Chemistry·Yogesh A SonawaneAmarnath Natarajan
Sep 4, 2016·Surgical Oncology Clinics of North America·Aimee M Crago, Mark A Dickson
Jul 13, 2016·Journal of Clinical Pharmacology·Yanke YuDiane Wang
Sep 2, 2016·Future Oncology·Demosthenes E ZiogasDimitrios H Roukos
Sep 24, 2016·Cancer Treatment Reviews·Rosaria ChilàGiovanna Damia
Nov 5, 2016·International Journal of Pharmaceutics·Adam C FisherJanet Woodcock
Oct 16, 2016·Expert Review of Anticancer Therapy·Dimitrios ZardavasMartine Piccart
Dec 7, 2016·British Journal of Cancer·Stine DaldorffJürgen Geisler
Jan 10, 2017·Nature Communications·Tongzheng LiuZhenkun Lou
Jan 28, 2017·Nature Reviews. Cancer·Tobias Otto, Piotr Sicinski
Apr 20, 2017·Journal of Medicinal Chemistry·Andrew C FlickChristopher J O'Donnell
May 5, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H MamiyaM Najafzadeh
Jun 22, 2017·Chemical Communications : Chem Comm·Caroline M RobbSandeep Rana
May 21, 2017·The Journal of Investigative Dermatology·Matias A BustosDave S B Hoon
Mar 7, 2018·Proceedings of the National Academy of Sciences of the United States of America·Oya Cingöz, Stephen P Goff
Mar 14, 2018·Endocrine-related Cancer·Tiago Vieira AugustoCristina Amaral
Dec 16, 2017·International Journal of Cancer. Journal International Du Cancer·Claire A MartinKaren E Sheppard
Dec 22, 2017·F1000Research·Philip Hinds, Jodie Pietruska
Mar 22, 2016·Biomarkers in Cancer·Kazushi Inoue, Elizabeth A Fry
Jan 9, 2018·Journal of Cutaneous Medicine and Surgery·Joanie PinardJoseph F Merola
May 17, 2018·Breast Cancer Research and Treatment·G HosteP Neven
Sep 14, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew D SeidmanLarissa A Korde
Oct 15, 2018·Journal of Cellular Biochemistry·Irem Dogan TuracliAbdullah Ekmekci
Apr 23, 2019·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Shen ShenZhenfeng Duan
Oct 6, 2017·Molecular Systems Biology·Míriam Tarrado-CastellarnauMarta Cascante
Oct 2, 2019·Future Medicinal Chemistry·Wenhai HuangZhengrong Shen
Dec 14, 2017·Breast Cancer Research and Treatment·Hehui FangXiaoxiang Guan
Mar 21, 2016·Current Protocols in Pharmacology·Jerry UsaryCharles M Perou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.